Gavin Clark-Gartner
Stock Analyst at Evercore ISI Group
(2.27)
# 2,863
Out of 5,182 analysts
44
Total ratings
52.5%
Success rate
-4.33%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Gavin Clark-Gartner
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MGTX MeiraGTx Holdings | Maintains: Outperform | $20 → $18 | $9.13 | +97.15% | 1 | Apr 1, 2026 | |
| JSPR Jasper Therapeutics | Maintains: Outperform | $12 → $7 | $0.93 | +652.77% | 5 | Apr 1, 2026 | |
| DMRA Damora Therapeutics | Initiates: Outperform | $46 | $25.50 | +80.39% | 1 | Mar 25, 2026 | |
| MIRM Mirum Pharmaceuticals | Maintains: Outperform | $101 → $126 | $92.48 | +36.25% | 5 | Mar 4, 2026 | |
| ABBV AbbVie | Maintains: Outperform | $232 → $228 | $197.38 | +15.51% | 6 | Feb 5, 2026 | |
| DYN Dyne Therapeutics | Maintains: Outperform | $38 → $36 | $18.04 | +99.56% | 1 | Dec 15, 2025 | |
| VERA Vera Therapeutics | Maintains: Outperform | $75 → $97 | $37.28 | +160.19% | 1 | Dec 8, 2025 | |
| EVMN Evommune | Initiates: Outperform | $40 | $25.00 | +60.00% | 1 | Dec 1, 2025 | |
| FBRX Forte Biosciences | Initiates: Outperform | $65 | $26.74 | +143.08% | 1 | Nov 25, 2025 | |
| ARGX argenx SE | Maintains: Outperform | $775 → $910 | $783.74 | +16.11% | 5 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $5 | $1.49 | +235.57% | 1 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $15 → $6 | $2.91 | +106.19% | 2 | Dec 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $179 → $170 | $20.98 | +710.30% | 9 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $20 | $5.21 | +283.88% | 1 | Aug 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $201 → $206 | $272.75 | -24.47% | 1 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $22 | $4.41 | +398.87% | 1 | Oct 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $10 | $2.83 | +253.36% | 1 | May 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $60 | $131.45 | -54.36% | 1 | Oct 5, 2022 |
MeiraGTx Holdings
Apr 1, 2026
Maintains: Outperform
Price Target: $20 → $18
Current: $9.13
Upside: +97.15%
Jasper Therapeutics
Apr 1, 2026
Maintains: Outperform
Price Target: $12 → $7
Current: $0.93
Upside: +652.77%
Damora Therapeutics
Mar 25, 2026
Initiates: Outperform
Price Target: $46
Current: $25.50
Upside: +80.39%
Mirum Pharmaceuticals
Mar 4, 2026
Maintains: Outperform
Price Target: $101 → $126
Current: $92.48
Upside: +36.25%
AbbVie
Feb 5, 2026
Maintains: Outperform
Price Target: $232 → $228
Current: $197.38
Upside: +15.51%
Dyne Therapeutics
Dec 15, 2025
Maintains: Outperform
Price Target: $38 → $36
Current: $18.04
Upside: +99.56%
Vera Therapeutics
Dec 8, 2025
Maintains: Outperform
Price Target: $75 → $97
Current: $37.28
Upside: +160.19%
Evommune
Dec 1, 2025
Initiates: Outperform
Price Target: $40
Current: $25.00
Upside: +60.00%
Forte Biosciences
Nov 25, 2025
Initiates: Outperform
Price Target: $65
Current: $26.74
Upside: +143.08%
argenx SE
Oct 31, 2025
Maintains: Outperform
Price Target: $775 → $910
Current: $783.74
Upside: +16.11%
Apr 29, 2025
Initiates: Outperform
Price Target: $5
Current: $1.49
Upside: +235.57%
Dec 20, 2024
Downgrades: In-Line
Price Target: $15 → $6
Current: $2.91
Upside: +106.19%
Nov 7, 2024
Maintains: Outperform
Price Target: $179 → $170
Current: $20.98
Upside: +710.30%
Aug 19, 2024
Initiates: Outperform
Price Target: $20
Current: $5.21
Upside: +283.88%
Aug 12, 2024
Maintains: Outperform
Price Target: $201 → $206
Current: $272.75
Upside: -24.47%
Oct 3, 2023
Initiates: Outperform
Price Target: $22
Current: $4.41
Upside: +398.87%
May 30, 2023
Maintains: Outperform
Price Target: $20 → $10
Current: $2.83
Upside: +253.36%
Oct 5, 2022
Maintains: Outperform
Price Target: $54 → $60
Current: $131.45
Upside: -54.36%